As an ever-increasing number of complex surgeries are regularly being performed in an outpatient setting at ambulatory surgical centers, some brain tumor resections may be safe and feasible for appropriately selected patients, new research suggests. Unadjusted results from a large feasibility study that included more than 300 patients who underwent craniotomy for resection of meningioma showed that among those who were treated in an outpatient setting, mortality and complication rates were significantly lower than for their inpatient counterparts.
News
Jul 10, 2020
Scientists are ready to try a new cancer vaccine in humans following the successful outcome of their preclinical studies. The new vaccine was developed by a Mater Research team based at The Translational Research Institute in collaboration with The University of Queensland. Lead Researcher Associate Professor Kristen Radford says the vaccine has the potential to treat a variety of blood cancers and malignancies and is a major breakthrough for cancer vaccinations.
Jul 10, 2020
Indiana University School of Medicine researchers Milan Radovich, Ph.D., and Bryan Schneider, MD, have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood who have undergone chemotherapy prior to surgery for the treatment of stage 1, 2 or 3 triple-negative breast cancer are critical indicators for the prediction of disease recurrence and disease-free survival.
Journal Abstracts
Jul 10, 2020
Marcel P. Trefny et.al. conducted a study to assess that ntratumoral Natural killer cells from Non-Small Cell Lung Cancer patients expressed elevated levels of the immune checkpoint receptor PD-1 on their cell surface. The researchers concluded that therapeutic potential of PD-1+ Natural killer cells in immune checkpoint blockade and could guide the development of Natural killer cell-stimulating agents in combination with PD-1 blockade.
Jul 10, 2020
Alec Britt et.al. conducted a study to assess if poor outcomes extend to patients with all types of ch17 abnormalities and the impact of concomitant TP53 gene mutations assessed by next-generation sequencing on prognosis. The researchers concluded that AML/MDS patients with ch17 abnormalities have poor outcomes with or without hematopoietic cell transplant . The results show that patients with ch17 abnormalities and TP53 mutations have a significantly poorer survival compared to patients who have ch17 abnormalities but no TP53 mutations.
Jul 10, 2020
Aaron D.Goldberg et.al. conducted a study to safety, activity, pharmacokinetics (PK), and immunogenicity of camidanlumab tesirine in patients with relapsed/refractory acute lymphoblastic leukemia/acute myeloid leukemia. The researchers concluded that signal for serious immune-related adverse eventss such as Guillain-Barré syndrome/polyradiculopathy was observed and there was no evidence of immunogenicity. PK showed rapid clearance with apparent half-life <2 days for conjugated and total antibody, suggesting that Q3W dosing may be insufficient for therapeutic efficacy, and prompting exploration of a QW schedule.
Recent Articles
Jul 10, 2020
Lung cancer is the most commonly diagnosed cancer worldwide and the leading cause of cancer-related deaths, killing more per year than breast, colon, and prostate cancers combined. Over the years, studies of the lung cancer genome have fueled the development of drug therapies that target mutations in specific genes and pathways. But despite these advances, survival among lung cancer patients remains low (below 20 percent).
Jul 10, 2020
Scientists are ready to try a new cancer vaccine in humans following the successful outcome of their preclinical studies. The new vaccine was developed by a Mater Research team based at The Translational Research Institute in collaboration with The University of Queensland. Lead Researcher Associate Professor Kristen Radford says the vaccine has the potential to treat a variety of blood cancers and malignancies and is a major breakthrough for cancer vaccinations.
Jul 10, 2020
Indiana University School of Medicine researchers Milan Radovich, Ph.D., and Bryan Schneider, MD, have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood who have undergone chemotherapy prior to surgery for the treatment of stage 1, 2 or 3 triple-negative breast cancer are critical indicators for the prediction of disease recurrence and disease-free survival.
Clinical Research
Jun 01, 2020
The purpose of this study is to find the most effective dose of radiation therapy to give to breast tumors in a shorter period of time, prior to standard partial mastectomy/axillary surgery.
Jun 01, 2020
This research study is being done to understand how patients with chronic cancer pain take their long-acting opioid medications and to develop an intervention to enhance cancer pain management.
Feb 27, 2020
Christopher G. Brennan-Jones et.al. identified specific strategies which have shown effectiveness in reducing workplace noise. These include implementation of stricter legislation and also stress upon the need for training in the proper use of earplugs and earmuffs so as to reduce noise exposure to safe levels.
Publications
Jun 26, 2020
In patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), a once-daily oral regimen of ibrutinib and venetoclax was associated with deep molecular remissions in both bone marrow and peripheral blood, including in patients with high-risk disease, according to investigators in phase 2 CAPTIVATE MRD trial.
Jun 04, 2020
Georgios Tsakonas et.al. conducted a study to understand the alterations in gene expression in brain metastasis versus primary tumour as it may increase aggressiveness and impair therapeutic efforts. The researchers concluded identified a unique gene downregulation pattern in brain metastases compared with primary tumours. This finding may explain the lower intracranial efficacy of systemic therapy, especially immunotherapy, in brain metastasis of patients with non–small-cell lung cancer.
Jun 01, 2020
Advance in Cancer Prevention addresses all types of cancer, how cancer forms in the body, and their prevention. It focuses on Cancer Vaccines, Chemotherapy, Radioactive Iodine Therapy, Breast Reconstruction Surgery, Mammography, Chemoprevention, aromatase inhibitors, Scintimammography, Oncoplastic surgery, Sumoylation, Dietary Supplements, Cancer Screening, Cancer and Nutrition, Exercise and Cancer, Alternative Cancer Medicines, Stem cell transplants for cancer prevention, Naturopathic Treatments, Clinical Naturopathy, Cancer Prevention from nuts.
Videos
Jul 10, 2020
Watch Dr. Jamie Studts discuss the quality implementation of lung cancer screening and share his thoughts on optimizing community-based implementation.
Jul 03, 2020
This is a recording of the American Lung Association’s Lung Cancer Precision Medicine Summit which took place on June 18, 2020. Oncologists Dr. Erin Schenk and Dr. Ibiayi Dagogo-Jack discuss which precision medicine treatment is available for lung cancer patients and promising new research. Carly Ornstein, National Director of Lung Cancer Education, gives a high-level overview of precision medicine and discusses new resources.
Jul 03, 2020
This is a recording of the American Lung Association’s Lung Cancer Precision Medicine Summit which took place on June 18, 2020. Oncologists Dr. Erin Schenk and Dr. Ibiayi Dagogo-Jack discuss which precision medicine treatment is available for lung cancer patients and promising new research. Carly Ornstein, National Director of Lung Cancer Education, gives a high-level overview of precision medicine and discusses new resources.
Jul 03, 2020
Dr. Pasi Janne, Director of Dana-Farber Cancer Institute’s Lowe Center for Thoracic Oncology and Belfer Center for Applied Cancer Science, and colleagues discuss how COVID-19 is changing the screening, management, and treatment of thoracic cancer, including:
- The impact on lung cancer screening
- The role of telemedicine in caring for cancer patients
- Managing clinical trials
Case Studies
Jun 24, 2020
Polycythemia vera is one of the myeloproliferative neoplasms that is distinguished by the uncontrolled production of blood cells and an increased red cell mass due to acquired JAK2 mutation. It has many complications and it might increase the risk of other tumors. However, it does not cause hypercalcemia and is rarely associated with parathyroid adenoma. Ahmed M. Abdalhadi and Mohamed A. Yassin report on a 64-year-old female with polycythemia vera found to have hypercalcemia due to parathyroid adenoma.
Jun 22, 2020
Durvalumab, a programmed cell death ligand 1 inhibitor, induces various immune-related adverse events (irAEs), including lung injury. However, diffuse alveolar hemorrhage (DAH) is a rare type of lung injury due to immune checkpoint inhibitors. A 76-year-old man with c-stage IIIA squamous cell carcinoma of the lung received maintenance durvalumab therapy after chemoradiotherapy. He developed dyspnea and malaise after 11 cycles of durvalumab. Chest computed tomography showed rapidly spreading bilateral ground-glass opacity in the lungs. We diagnosed DAH by hemosiderin-laden macrophages in bloody bronchoalveolar lavage fluid. Despite mechanical ventilation, steroids, and cyclophosphamide, he died of respiratory failure. The autopsy revealed that fresh and old bleeding areas coexisted, and neither pulmonary vasculitis nor diffuse alveolar damage was detected microscopically. Furthermore, CD3+ and CD8+ lymphocytes were observed in the lung interstitium, whereas CD20+ and CD4+ lymphocytes were scarcely detected. We report the first case of durvalumab-induced DAH. We should be alert to irAEs with DAH as a potential differential diagnosis of lung injury during durvalumab treatment.
Jun 19, 2020
Only three cases of patients suffering from a localized chronic form of Langerhans cell histiocytosis (LCH) successfully treated with radiofrequency ablation (RFA) have been published so far. This is the first case report of a patient with a localized chronic form of LCH of the femur, which was successfully treated with percutaneous image-guided RFA, and who was evaluated pre-RFA and followed up post-RFA for a period of 48 months, in order to validate the safety and efficacy of this method and to obtain imaging studies depicting the actual in situ changes taking place post-RFA. RFA was proved to be a safe and efficient method when treating patients with a localized chronic form of LCH.
Jun 19, 2020
Recent data suggest that BRCA mutation carriers younger than 40 may not benefit from mammography in addition to MRI. Our objective was to evaluate screening modalities utilized in a high-risk population. Clinicopathologic data were abstracted for patients followed in a high-risk clinic from 2007 to 2017. Three patients were diagnosed younger than 40, 1 on a mammogram, and 2 on MRI. The patient diagnosed on mammogram had no prior MRI and the lesion was seen on follow-up MRI. Interval screening MRI identified DCIS in BRCA patients with a previous normal mammogram and cancers diagnosed on mammograms were all identified on follow-up MRI. These findings support further evaluation of MRI alone until age 40 in BRCA mutation carriers.